Medicine and Dentistry
Patient
90%
Dextromethorphan Plus Quinidine
70%
Infusion
60%
Dyskinesia
60%
Placebo
60%
Parkinson's Disease
50%
Levodopa-Induced Dyskinesia
40%
Adverse Event
20%
Efficacy Study
20%
Sensitivity Analysis
10%
Metabolism
10%
Treatment Duration
10%
Rating Scale
10%
Medication Compliance
10%
Levodopa
10%
Dextromethorphan
10%
Sigma 1 Opiate Receptor
10%
Assessment
10%
Therapeutic Procedure
10%
Examination
10%
Amaurosis
10%
INIS
patients
90%
infusion
60%
nervous system diseases
50%
curves
30%
populations
20%
motors
20%
drugs
10%
compliance
10%
assessments
10%
metabolism
10%
safety
10%
receptors
10%
peaks
10%
washout
10%
sensitivity analysis
10%
Neuroscience
Dyskinesia
100%
Dextromethorphan Plus Quinidine
70%
Parkinson's Disease
50%
L-DOPA
50%
Placebo
30%
Receptor Agonists
10%
Sigma 1 Opiate Receptor
10%
Dextromethorphan
10%
Pharmacology, Toxicology and Pharmaceutical Science
Dextromethorphan Plus Quinidine
70%
Dyskinesia
60%
Parkinson Disease
50%
Levodopa-Induced Dyskinesia
40%
Adverse Event
20%
Receptor Agonist
10%
Dextromethorphan
10%
Levodopa
10%
Sigma 1 Opiate Receptor
10%
Blindness
10%